PepGen Inc.
PEPGNext catalyst
PGN-EDODM1
Myotonic Dystrophy 1
Get an email about PEPG's next catalysts
Track PepGen (PEPG) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
PEPG Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.27 | FQ end Sep/2026 | Call: tbd
PGN-EDODM1 Phase 2 Est. Readout (FREEDOM2-DM1)
Primary completion for PGN-EDODM1 trial (NCT06667453) in Myotonic Dystrophy 1
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PGN-EDODM1 | Phase 2 | Myotonic Dystrophy 1 | - | - |
Frequently asked questions
What is in PepGen Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in PepGen Inc.'s (PEPG) pipeline across Phase 2. Its lead program is PGN-EDODM1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PepGen Inc.'s next FDA catalyst?→
PepGen Inc.'s (PEPG) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PEPG biotech catalysts?→
Add PEPG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PepGen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.